Skip to main content Back to Top
Advertisement

12/22/2023

Galcanezumab-gnlm (Emgality)

Products Affected - Description

    • Emgality subcutaneous injection, Lilly USA, LLC, 100 mg/mL, 1 mL prefilled syringe, 3 count, NDC 00002-3115-09
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL pen, 1 count, NDC 00002-1436-11
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL pen, 2 count, NDC 00002-1436-27
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL prefilled syringe, 1 count, NDC 00002-2377-11
    • Emgality subcutaneous injection, Lilly USA, LLC, 120 mg/mL, 1 mL prefilled syringe, 2 count, NDC 00002-2377-27

Reason for the Shortage

    • Lilly has Emgality on shortage due to increased demand.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Lilly has all Emgality presentations on intermittent back order and the company is releasing product as it becomes available.

Updated

Created December 22, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT